Clinically relevant end points at 10 years among men treated within a national health care delivery system were examined . Median age at diagnosis was 65 years and median follow-up was 8.7 years . Most had intermediate (42%) and high-risk (33%) disease, with 40% receiving androgen deprivation therapy as part of initial therapy .